(Alliance News) - Arecor Therapeutics PLC on Tuesday said that it has signed an additional formulation study agreement with its top five global pharmaceutical partner, building on a collaboration formed in 2022. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review. Read More
(Alliance News) - Arecor Therapeutics PLC on Wednesday said its subsidiary Tetris Pharma Ltd has launched its Olguo treatment in Austria, the second European launch in its European roll-out strategy. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Posts a widened pretax loss of GBP5.2 million in the six months to June 30, from GBP3.5 million a year earlier. Revenue, however, increases by 51% to GBP693,000 from GBP460,000, derived from "formulation development projects, in line with expectations". Research & Development costs soared to GBP4.8 million from GBP1.9 million a year earlier, Cash amounts to GBP13.7 million at June 30, compared to GBP22.1 million a year ago. Read More
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Granted two patents by the European patent office protecting the company's formulations of adalimumab until 2038. Adalimumab is a biosimilar of AbbVie Inc's Humira which treats rheumatoid arthritis and Chohn's disease. Read More
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Agrees to acquire commercial stage pharmaceutical firm Tetris Pharma Ltd, which is expected to add a key commercial diabetes product to Arecor's portfolio. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Signs exclusive formulation study collaboration with an unnamed pharmaceutical company, under which Arecor will use its formulation technology platform Arestat to develop liquid formulations of its proprietary products. Read More
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Says it is making progress with two lead clinical stage programmes focused on diabetes. Says phase one clinical trial data for both lead product, AT247, an ultra-rapid insulin and for second product AT278, a concentrated rapid insulin targeting patients who require higher volumes of insulin, "excelled our expectations". Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
TRADING UPDATES: City Pub and Revolution Bars see Omicron hit Read More
TRADING UPDATES: GSTechnologies loss widens; DX Group launches review Read More